Compare Alliant Energy Corporation (LNT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Merck & Co., Inc. — how do they compare? Alliant Energy Corporation trades at $73.98 (market cap $19.10B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 16.1× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| LNT | MRK | |
|---|---|---|
Market Cap | $19.10B | $307.25B |
Sector | Utilities | Health |
52-Week High | $78.03 | $129.52 |
52-Week Low | $63.62 | $77.60 |
Enterprise Value | $30.83B | $350.66B |
Dividend Yield | 2.89% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $73.11, down 2.29% on the day, with a bullish technical outlook and strong analyst support. The stock shows steady revenue growth, improving net income margins to 18.58% in 2025, and consistent dividend payments. Recent news highlights its $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, driven by data center demand and grid modernization initiatives.
LNT presents a favorable risk-reward profile with a consensus price target of $78.50, offering 7.4% upside. Key risks include rising debt levels and execution of capital-intensive projects. The bullish analyst consensus (52% Buy) and institutional confidence support long-term growth, though investors should monitor interest rate sensitivity and regulatory developments.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
